Correlation Between Acrivon Therapeutics, and Adagene

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Acrivon Therapeutics, and Adagene at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Acrivon Therapeutics, and Adagene into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Acrivon Therapeutics, Common and Adagene, you can compare the effects of market volatilities on Acrivon Therapeutics, and Adagene and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Acrivon Therapeutics, with a short position of Adagene. Check out your portfolio center. Please also check ongoing floating volatility patterns of Acrivon Therapeutics, and Adagene.

Diversification Opportunities for Acrivon Therapeutics, and Adagene

0.85
  Correlation Coefficient

Very poor diversification

The 3 months correlation between Acrivon and Adagene is 0.85. Overlapping area represents the amount of risk that can be diversified away by holding Acrivon Therapeutics, Common and Adagene in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Adagene and Acrivon Therapeutics, is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Acrivon Therapeutics, Common are associated (or correlated) with Adagene. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Adagene has no effect on the direction of Acrivon Therapeutics, i.e., Acrivon Therapeutics, and Adagene go up and down completely randomly.

Pair Corralation between Acrivon Therapeutics, and Adagene

Given the investment horizon of 90 days Acrivon Therapeutics, Common is expected to under-perform the Adagene. In addition to that, Acrivon Therapeutics, is 1.79 times more volatile than Adagene. It trades about -0.09 of its total potential returns per unit of risk. Adagene is currently generating about -0.11 per unit of volatility. If you would invest  201.00  in Adagene on October 20, 2024 and sell it today you would lose (17.00) from holding Adagene or give up 8.46% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthStrong
Accuracy100.0%
ValuesDaily Returns

Acrivon Therapeutics, Common  vs.  Adagene

 Performance 
       Timeline  
Acrivon Therapeutics, 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Acrivon Therapeutics, Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unsteady performance in the last few months, the Stock's basic indicators remain fairly stable which may send shares a bit higher in February 2025. The latest fuss may also be a sign of long-term up-swing for the venture sophisticated investors.
Adagene 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Adagene has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unsteady performance in the last few months, the Stock's basic indicators remain nearly stable which may send shares a bit higher in February 2025. The current disturbance may also be a sign of long-run up-swing for the company stockholders.

Acrivon Therapeutics, and Adagene Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Acrivon Therapeutics, and Adagene

The main advantage of trading using opposite Acrivon Therapeutics, and Adagene positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Acrivon Therapeutics, position performs unexpectedly, Adagene can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Adagene will offset losses from the drop in Adagene's long position.
The idea behind Acrivon Therapeutics, Common and Adagene pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.

Other Complementary Tools

Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Share Portfolio
Track or share privately all of your investments from the convenience of any device